FDA Action Alert: BMS, GSK, Aldeyra and More

Why It Matters

These rulings will shape market entry for multi‑billion‑dollar specialty therapies and signal the FDA’s stance on novel, often orphan, indications.

Key Takeaways

• FDA decisions due March 2025 for five major applications
• BMS seeks psoriatic arthritis label, 54.2% ACR20 response
• Aldeyra's reproxalap third FDA review after two rejections
• Rhythm's Imcivree cuts BMI 19.8% in rare obesity
• GSK's linerixibat improves itch scores in primary biliary cholangitis

Pulse Analysis

The FDA’s March 2025 action slate places five high‑profile applications under a tight deadline, highlighting the agency’s role in shaping the next wave of specialty therapeutics. With two submissions delayed from the previous year, the schedule underscores how timing and data completeness can dictate market entry for both large‑cap and niche biotech firms. Stakeholders are watching closely as the outcomes will not only affect individual product launches but also signal the regulator’s appetite for novel mechanisms in dermatology, ophthalmology, metabolic, hepatic and genetic therapies.

BMS is leveraging robust Phase 3 data—54.2% of psoriatic arthritis patients achieved ACR20 versus 39.4% on placebo—to pursue an indication expansion for Sotyktu, potentially adding a multi‑billion‑dollar revenue stream to its psoriasis franchise. Aldeyra’s reproxalap, after two prior rejections, now carries fresh ocular‑discomfort data that could finally unlock a market estimated at $1 billion globally. Rhythm’s MC4R agonist Imcivree demonstrated a 19.8% BMI reduction, positioning it as a rare‑obesity breakthrough, while GSK’s linerixibat could become the first oral therapy to alleviate cholestatic itch in primary biliary cholangitis. Rocket’s gene‑therapy Kresladi, with 100% 12‑month survival in Phase 1/2, targets an ultra‑rare immunodeficiency affecting roughly 300 patients worldwide.

The clustering of these decisions illustrates a broader shift toward accelerated pathways for high‑need conditions, where regulators balance rigorous evidence with patient‑centric urgency. Successful approvals would not only expand therapeutic options but also reinforce investor confidence in specialty drug pipelines, potentially driving higher valuations for companies that can demonstrate differentiated efficacy. Conversely, setbacks could prompt tighter scrutiny of trial designs and manufacturing controls, especially for complex modalities like gene therapy. Market watchers will therefore gauge each outcome as a bellwether for future FDA engagement with innovative, often orphan, indications.